Revenue Breakdown
Composition ()
No data
Revenue Streams
Novartis (NVS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Rest of portfolio, accounting for 18.4% of total sales, equivalent to $2.56B. Other significant revenue streams include Cardiovascular, Renal and Metabolism - Entresto and Immunology - Cosentyx. Understanding this composition is critical for investors evaluating how NVS navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Novartis maintains a gross margin of 74.44%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 30.08%, while the net margin is 17.34%. These profitability ratios, combined with a Return on Equity (ROE) of 31.01%, provide a clear picture of how effectively NVS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, NVS competes directly with industry leaders such as AZN and MRK. With a market capitalization of $318.41B, it holds a leading position in the sector. When comparing efficiency, NVS's gross margin of 74.44% stands against AZN's 78.89% and MRK's 74.15%. Such benchmarking helps identify whether Novartis is trading at a premium or discount relative to its financial performance.
